# Development of an Optimized Adjuvanted TB Vaccine

> **NIH NIH N01** · UNIVERSITY OF MONTANA · 2022 · $2,076,197

## Abstract

Vaccine Adjuvant Discovery Program: To develop a lead, optimized adjuvanted tuberculosis (TB) vaccine for IM or IN administration using specified adjuvants in combination with recombinant or circRNA TB antigens within the context
of a vaccine to prevent TB.

## Key facts

- **NIH application ID:** 10681631
- **Project number:** 75N93019C00045-P00012-9999-3
- **Recipient organization:** UNIVERSITY OF MONTANA
- **Principal Investigator:** JAY EVANS
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,076,197
- **Award type:** —
- **Project period:** 2021-09-30 → 2022-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10681631

## Citation

> US National Institutes of Health, RePORTER application 10681631, Development of an Optimized Adjuvanted TB Vaccine (75N93019C00045-P00012-9999-3). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10681631. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*